Faculty
Doug Adkins.jpg

Douglas R. Adkins, MD

Professor
Department of Medicine
Oncology Division
Medical Oncology

Clinical Interests

  • Head and neck cancer
  • Sarcoma
  • Thyroid cancer

Contact

  • 314-747-8475 (tel)
  • 314-362-7086 (fax)
  • 11th Floor Mid-Campus Center (office)
  • Division of Oncology
    Campus Box 8056
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110

Peer-reviewed Manuscripts

  • Comparison of Unilateral Versus Bilateral Intensity-Modulated Radiotherapy for Surgically Treated Squamous Cell Carcinoma of the Palatine Tonsil
    Chin RI, Rao YJ, Hwang MY, Spencer CR, Pierro M, DeWees T, Patel P, Sinha P, Gay HA, Daly M, Haughey BH, Nussenbaum B, Adkins DR, Lewis JS Jr, Thorstad WL
    Cancer 2017 Sep 7; [Epub ahead of print]
  • Outcomes of surgically treated human papillomavirus-related oropharyngeal squamous cell carcinoma with N3 disease
    Zenga J, Haughey BH, Jackson RS, Adkins DR, Aranake-Chrisinger J, Bhatt N, Gay HA, Kallogjeri D, Martin EJ, Moore EJ, Paniello RC, Rich JT, Thorstad WL, Nussenbaum B
    Laryngoscope 2017 Sep;127(9):2033-2037
  • Trials in head and neck oncology: Evolution of perioperative adjuvant therapy
    Zenga J, Pipkorn P, Adkins DR, Thorstad WL, Nussenbaum B
    Oral Oncol 2017 Sep;72:80-89
  • nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma
    Adkins D, Ley J, Oppelt P, Wildes TM, Gay HA, Daly M, Rich J, Paniello RC, Jackson R, Pipkorn P, Nussenbaum B, Trinkaus K, Thorstad W
    Oral Oncol 2017 Sep;72:26-31
  • Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients
    Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Scott Z, Elder J, Sonis ST, Straube R, Donini O
    Biotechnol Rep (Amst) 2017 May 17;15:24-26
  • NCCN guidelines insights: head and neck cancers, version 2.2017
    Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL Jr, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD
    J Natl Compr Canc Netw 2017 Jun;15(6):761-770
  • Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study
    Azad NS, El-Khoueiry A, Yin J, Oberg AL, Flynn P, Adkins D, Sharma A, Weisenberger DJ, Brown T, Medvari P, Jones PA, Easwaran H, Kamel I, Bahary N, Kim G, Picus J, Pitot HC, Erlichman C, Donehower R, Shen H, Laird PW, Piekarz R, Baylin S, Ahuja N
    Oncotarget 2017 May 23;8(21):35326-35338
  • Biomarker and tumor responses of oral cavity squamous cell carcinoma to trametinib: a phase II neoadjuvant window-of-opportunity clinical trial
    Uppaluri R, Winkler AE, Lin T, Law JH, Haughey BH, Nussenbaum B, Paniello RC, Rich JT, Diaz JA, Michel LP, Wildes T, Dunn GP, Zolkind P, Kallogjeri D, Piccirillo JF, Dehdashti F, Siegel BA, Chernock RD, Lewis JS Jr, Adkins DR
    Clin Cancer Res 2017 May 1;23(9):2186-2194
  • NCCN guidelines insights: bone cancer, version 2.2017
    Biermann JS, Chow W, Reed DR, Lucas D, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Budd GT, Curry WT, Didwania A, Fabbri N, Hornicek FJ, Kuechle JB, Lindskog D, Mayerson J, McGarry SV, Million L, Morris CD, Movva S, O'Donnell RJ, Randall RL, Rose P, Santana VM, Satcher RL, Schwartz H, Siegel HJ, Thornton K, Villalobos V, Bergman MA, Scavone JL
    J Natl Compr Canc Netw 2017 Feb;15(2):155-167
  • Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel
    Ley J, Wildes TM, Daly K, Oppelt P, Adkins D
    Med Oncol 2017 Feb;34(2):28
  • Correlation of Ki-67 proliferative antigen expression and tumor response to induction chemotherapy containing cell cycle-specific agents in head and neck squamous cell carcinoma
    Chatzkel J, Lewis JS Jr, Ley JC, Wildes TM, Thorstad W, Gay H, Daly M, Jackson R, Rich J, Paniello R, Nussenbaum B, Liu J, Siegel BA, Dehdashti F, Adkins D
    Head Neck Pathol 2016 Dec 26; [Epub ahead of print]
  • Dusquetide: a novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study
    Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Elder J, Sonis ST, Straube R, Donini O
    J Biotechnol 2016 Dec 10;239:115-125
  • Reevaluation of postoperative radiation dose in the management of human papillomavirus-positive oropharyngeal cancer
    Chin RI, Spencer CR, DeWees T, Hwang MY, Patel P, Sinha P, Gay HA, Haughey BH, Nussenbaum B, Adkins DR, Lewis JS Jr, Thorstad WL
    Head Neck 2016 Nov;38(11):1643-1649
  • A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas
    Bean GR, Kremer JC, Prudner BC, Schenone AD, Yao JC, Schultze MB, Chen DY, Tanas MR, Adkins DR, Bomalaski J, Rubin BP, Michel LS, Van Tine BA
    Cell Death Dis 2016 Oct 13;7(10):e2406
  • PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck
    Wirth LJ, Dakhil S, Kornek G, Axelrod R, Adkins D, Pant S, O'Brien P, Debruyne PR, Oliner KS, Dong J, Murugappan S
    Oral Oncol 2016 Oct;61:31-40
  • nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma
    Adkins D, Ley J, Michel L, Wildes TM, Thorstad W, Gay HA, Daly M, Rich J, Paniello R, Uppaluri R, Jackson R, Trinkaus K, Nussenbaum B
    Oral Oncol 2016 Oct;61:1-7
  • Phase 1b trial of superoxide (SO) dismutase (SOD) mimetic GC4419 to reduce chemoradiation therapy (CRT)-induced oral mucositis (OM) in patients (pts) with oral cavity or oropharyngeal carcinoma (OCC)
    Anderson CM, Allen BG, Sun W, Agarwala SS, Lee CM, Venigalla ML, Greenberg L, Adkins D, Chen Y, Zhen W, Mould DR, Holmlund J, Brill J, Sonis ST, Buatti J
    Int J Radiat Oncol Biol Phys 2016 Oct 1;96(2S):S83-S84
  • Predictors of acute throat or esophageal pain during radiation therapy for head and neck cancer
    Gay HA, Deasy JO, Apte A, Daly MD, Adkins D, Rich JT, Michel L, Wildes T, Dyk PT, Mullen D, Eschen L, Chin RI, Nussenbaum B, Haughey BH, Thorstad WL, Oh JH
    Int J Radiat Oncol Biol Phys 2016 Oct 1;96(2S):E392-E393
  • Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
    Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R Jr, Conti I, Cosaert J, Schwartz GK
    Lancet 2016 Jul 30;388(10043):488-97
  • High E6 gene expression predicts for distant metastasis and poor survival in patients with HPV-positive oropharyngeal squamous cell carcinoma
    Khwaja SS, Baker C, Haynes W, Spencer CR, Gay H, Thorstad W, Adkins DR, Nussenbaum B, Chernock RD, Lewis JS Jr, Wang X
    Int J Radiat Oncol Biol Phys 2016 Jul 15;95(4):1132-41
  • Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma
    Michel L, Ley J, Wildes TM, Schaffer A, Robinson A, Chun SE, Lee W, Lewis J Jr, Trinkaus K, Adkins D
    Oral Oncol 2016 Jul;58:41-8
  • Improved clinical trial enrollments for uterine leiomyosarcoma patients after gynecologic oncology partnership with a sarcoma center
    Lange SE, Liu J, Adkins DR, Powell MA, Van Tine BA, Mutch DG
    Gynecol Oncol 2016 Feb;140(2):307-312
  • Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen
    Soulieres D, Aguilar JL, Chen E, Misiukiewicz K, Ernst S, Lee HJ, Bryant K, He S, Obasaju CK, Chang SC, Chin S, Adkins D
    BMC Cancer 2016 Jan 14;16(1):19
  • Treatment Outcomes for T4 Oropharyngeal Squamous Cell Carcinoma
    Zenga J, Wilson M, Adkins DR, Gay HA, Haughey BH, Kallogjeri D, Michel LS, Paniello RC, Rich JT, Thorstad WL, Nussenbaum B
    JAMA Otolaryngol Head Neck Surg 2015 Dec 1;141(12):1118-27
  • Epidermal growth factor receptor expression in spindle cell carcinomas of the head and neck
    Watson RF, Chernock RD, Zhang KH, Michel LS, Adkins DR, El-Mofty SK, Lewis JS Jr
    Head Neck Pathol 2015 Sep;9(3):360-8
  • Nab-paclitaxel-based compared to docetaxel-based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck
    Schell A, Ley J, Wu N, Trinkaus K, Wildes TM, Michel L, Thorstad W, Gay H, Lewis J, Rich J, Diaz J, Paniello RC, Nussenbaum B, Adkins DR
    Cancer Med 2015 Apr;4(4):481-9
  • Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma
    D' Angelo SP, Mahoney MR, Van Tine BA, Adkins DR, Perdekamp MT, Condy MM, Luke JJ, Hartley EW, Antonescu CR, Tap WD, Schwartz GK
    Cancer Chemother Pharmacol 2015 Mar;75(3):629-38
  • Pre-radiotherapy feeding tube identifies a poor prognostic subset of postoperative p16 positive oropharyngeal carcinoma patients
    Verma V, Liu J, Eschen L, Danieley J, Spencer C, Lewis JS Jr, Diaz J, Piccirillo JF, Adkins DR, Nussenbaum B, Thorstad WL, Gay HA
    Radiat Oncol 2015 Jan 9;10(1):8
  • A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
    Jimeno A, Bauman JE, Weissman C, Adkins D, Schnadig I, Beauregard P, Bowles DW, Spira A, Levy B, Seetharamu N, Hausman D, Walker L, Rudin CM, Shirai K
    Oral Oncol 2015 Apr;51(4):383-8
  • Outcomes of P16 positive oropharyngeal squamous cell carcinoma treated with surgery and adjuvant IMRT
    Gay HA, Liu J, Spencer CR, Lewis JS Jr, Diaz J, Nussenbaum B, Piccirillo JF, Ferraro DJ, Wildes T, Sinha P, Adkins DR, Haughey BH, Thorstad WL
    J Radiat Oncol 2015 Mar;4(1):37-46
  • Eliminating radiotherapy to the contralateral retropharyngeal and high level II lymph nodes in head and neck squamous cell carcinoma is safe and improves quality of life
    Spencer CR, Gay HA, Haughey BH, Nussenbaum B, Adkins DR, Wildes TM, DeWees TA, Lewis JS Jr, Thorstad WL
    Cancer 2014 Dec 15;120(24):3994-4002
  • Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma
    Chawla SP, Cranmer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE, Adkins DR, Hendifar AE, Kroll S, Ganjoo KN
    J Clin Oncol 2014 Oct 10;32(29):3299-306
  • Metastasis occurring eleven years after diagnosis of human papilloma virus-related oropharyngeal squamous cell carcinoma
    Ley J, Wildes T, El-Mofty S, Adkins D
    Ecancermedicalscience 2014 Nov 13;8:480
  • Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC
    Zhang K, Jones L, Lim S, Maher CA, Adkins D, Lewis J, Kimple RJ, Fertig EJ, Chung CH, Van Tine BA, Ellis MJ, Herrlich A, Michel LS
    Oncotarget 2014 Oct 15;5(19):9281-94
  • Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
    Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Pena C, Molnar I, Schlumberger MJ
    DECISION investigators (Contributors include: Adkins D)

    Lancet 2014 Jul 26;384(9940):319-28
  • A prospective trial comparing FDG-PET/CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck
    Adkins D, Ley J, Dehdashti F, Siegel MJ, Wildes TM, Michel L, Trinkaus K, Siegel BA
    Cancer Med 2014 Dec;3(6):1493-501
  • Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neck
    Touma W, Koro SS, Ley J, Wildes TM, Michel L, Tao Y, Adkins D
    Oral Oncol 2014 Sep;50(9):895-900
  • Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy
    Schenone AD, Luo J, Montgomery L, Morgensztern D, Adkins DR, Van Tine BA
    Cancer Med 2014 Jun;3(3):603-12
  • Distant metastasis in p16-positive oropharyngeal squamous cell carcinoma: A critical analysis of patterns and outcomes
    Sinha P, Thorstad WT, Nussenbaum B, Haughey BH, Adkins DR, Kallogjeri D, Lewis JS Jr
    Oral Oncol 2014 Jan;50(1):45-51
  • An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours
    Schoffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, Pennock GK, Youssoufian H, Gelderblom H, Willey R, Grebennik DO
    Eur J Cancer 2013 Oct;49(15):3219-28
  • A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)
    Limaye S, Riley S, Zhao S, O'Neill A, Posner M, Adkins D, Jaffa Z, Clark J, Haddad R
    Oral Oncol 2013 Aug;49(8):835-41
  • Bone cancer
    Biermann JS, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Butrynski JE, Cheong D, Chow W, Curry WT, Frassica DA, Frassica FJ, Hande KR, Hornicek FJ, Jones RL, Mayerson J, McGarry SV, McGrath B, Morris CD, O'Donnell RJ, Randall RL, Santana VM, Satcher RL, Siegel HJ, von Mehren M, Bergman MA, Sundar H
    J Natl Compr Canc Netw 2013 Jun 1;11(6):688-723
  • Antiangiogenic agents for nonmalignant brain tumors
    Hawasli AH, Rubin JB, Tran DD, Adkins DR, Waheed S, Hullar TE, Gutmann DH, Evans J, Leonard JR, Zipfel GJ, Chicoine MR
    J Neurol Surg B Skull Base 2013 Jun;74(3):136-41
  • Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
    Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG
    Lancet Oncol 2013 Apr;14(4):371-82
  • Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
    Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M
    Lancet Oncol 2013 Mar;14(3):257-64
  • A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck
    Adkins D, Ley J, Trinkaus K, Thorstad W, Lewis J Jr, Wildes T, Siegel BA, Dehdashti F, Gay H, Mehan P, Nussenbaum B
    Cancer 2013 Feb 15;119(4):766-73
  • Cisplatin versus cetuximab given concurrently with definitive radiation therapy for locally advanced head and neck squamous cell carcinoma
    Ley J, Mehan P, Wildes TM, Thorstad W, Gay HA, Michel L, Nussenbaum B, Trinkaus K, Adkins D
    Oncology 2013;85(5):290-6
  • Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an Eastern Cooperative Oncology Group trial
    Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, Burtness B, Forastiere AA
    J Clin Oncol 2013 Apr 10;31(11):1405-14
  • Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy
    Demetri GD, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, Penel N, Riedel RF, Bui-Nguyen B, Cranmer LD, Reichardt P, Bompas E, Alcindor T, Rushing D, Song Y, Lee RM, Ebbinghaus S, Eid JE, Loewy JW, Haluska FG, Dodion PF, Blay JY
    J Clin Oncol 2013 Jul 1;31(19):2485-92
  • Prognostic value of F-FDG PET metabolic parameters in oropharyngeal squamous cell carcinoma
    Garsa AA, Chang AJ, Dewees T, Spencer CR, Adkins DR, Dehdashti F, Gay HA, Thorstad WL
    J Radiat Oncol 2013 Mar;2(1):27-34
  • Head and neck carcinoma in the United States: First comprehensive report of the Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN)
    Ang KK, Chen A, Curran WJ Jr, Garden AS, Harari PM, Murphy BA, Wong SJ, Bellm LA, Schwartz M, Newman J, Adkins D, Hayes DN, Parvathaneni U, Brachman D, Ghabach B, Schneider CJ, Greenberg M, Anne PR
    Cancer 2012 Dec 1;118(23):5783-92
  • Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study
    Urba S, van Herpen CM, Sahoo TP, Shin DM, Licitra L, Mezei K, Reuter C, Hitt R, Russo F, Chang SC, Hossain AM, Frimodt-Moller B, Koustenis A, Hong RL
    Cancer 2012 Oct 1;118(19):4694-705
  • Radiotherapeutic management of cervical lymph node metastases from an unknown primary site
    Perkins SM, Spencer CR, Chernock RD, Haughey BH, Nussenbaum B, Adkins DR, Kuperman DI, Thorstad WL
    Arch Otolaryngol Head Neck Surg 2012 Jul;138(7):656-61
  • A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma
    Ganjoo KN, Cranmer LD, Butrynski JE, Rushing D, Adkins D, Okuno SH, Lorente G, Kroll S, Langmuir VK, Chawla SP
    Oncology 2011;80(1-2):50-6
  • A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C)
    Okuno S, Bailey H, Mahoney MR, Adkins D, Maples W, Fitch T, Ettinger D, Erlichman C, Sarkaria JN
    Cancer 2011 Aug 1;117(15):3468-75
  • Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial
    Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR; TAX 324 Study Group
    Lancet Oncol 2011 Feb;12(2):153-9
  • Squamous cell cancer of the head and neck with distant metastasis at presentation
    Kuperman DI, Auethavekiat V, Adkins DR, Nussenbaum B, Collins S, Boonchalermvichian C, Trinkaus K, Chen L, Morgensztern D
    Head Neck 2011 May;33(5):714-8
  • A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies
    Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, Adkins DR, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, Wright LP, Guo Z, Ryan CE, Tao Y, Soares EM, Cai SR, Lin L, Dancey J, Rudek MA, McLeod HL, Piwnica-Worms H
    Cancer Chemother Pharmacol 2011 Jun;67(6):1225-37
  • How do I treat and prevent hypersensitivity reactions due to cetuximab?
    Adkins D
    Oncology Times 2011;8:21
  • Bone cancer
    Biermann JS, Adkins DR, Benjamin RS, Brigman B, Chow W, Conrad EU 3rd, Frassica DA, Frassica FJ, George S, Hande KR, Hornicek FJ, Letson GD, Mayerson J, McGarry SV, McGrath B, Morris CD, O'Donnell RJ, Randall RL, Santana VM, Satcher RL, Siegel HJ, Somaiah N, Yasko AW
    J Natl Compr Canc Netw 2010 Jun;8(6):688-712
  • Transoral laser microsurgery (TLM) +/- adjuvant therapy for advanced stage oropharyngeal cancer: outcomes and prognostic factors
    Rich JT, Milov S, Lewis JS Jr, Thorstad WL, Adkins DR, Haughey BH
    Laryngoscope 2009 Sep;119(9):1709-19
  • Safety profile and clinical outcomes in a phase I, placebo-controlled study of siplizumab in acute graft-versus-host disease
    Adkins D, Ratanatharathorn V, Yang H, White B
    Transplantation 2009 Jul 27;88(2):198-202
  • Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation
    Posner MR, Norris CM, Wirth LJ, Shin DM, Cullen KJ, Winquist EW, Blajman CR, Mickiewicz EA, Frenette GP, Plinar LF, Cohen RB, Steinbrenner LM, Freue JM, Gorbunova VA, Tjulandin SA, Raez LE, Adkins DR, Tishler RB, Roessner MR, Haddad RI
    Ann Oncol 2009 May;20(5):921-7
  • Total body irradiation before an allogeneic stem cell transplantation: is there a magic dose?
    Adkins D, DiPersio JF
    Curr Opin Hematol 2008 Nov;15(6):555-60
  • Early outcomes after allogeneic hematopoietic SCT in pediatric patients with hematologic malignancies following single fraction TBI
    Druley TE, Hayashi R, Mansur DB, Zhang QJ, Barnes Y, Trinkaus K, Witty S, Thomas T, Klein EE, DiPersio JF, Adkins D, Shenoy S
    Bone Marrow Transplant 2009 Feb;43(4):307-14
  • Temporal relationship between antitumor necrosis factor-alpha antibody therapy and recrudescence of head and neck squamous cell carcinoma
    Engel SH, Hullar TE, Adkins DR, Thorstad WL, Sunwoo JB
    Laryngoscope 2008 Mar;118(3):450-2
  • Prognostic significance of early lymphocyte recovery after post-autografting administration of GM-CSF in non-Hodgkin's lymphoma
    Tiwari D, Gao F, Hidalgo J, Adkins DR, Vij R, Dipersio JF, Khoury HJ
    Bone Marrow Transplant 2007 Oct;40(7):671-5
  • A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation
    Fong T, Trinkaus K, Adkins D, Vij R, Devine SM, Tomasson M, Goodnough LT, Lopez S, Graubert T, Shenoy S, Dipersio JF, Khoury HJ
    Biol Blood Marrow Transplant 2007 Oct;13(10):1201-6
  • Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide
    Hallemeier CL, Girgis MD, Blum WG, Brown RA, Khoury HJ, Devine SM, Vij R, Lin HS, DiPersio JF, Adkins DR
    Biol Blood Marrow Transplant 2006 Jul;12(7):749-57
  • Granulocyte-colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usage
    Oza A, Hallemeier C, Goodnough L, Khoury H, Shenoy S, Devine S, Augustin K, Vij R, Trinkaus K, Dipersio JF, Adkins D
    Transfusion 2006 Jan;46(1):14-23
  • Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone
    Devine SM, Brown RA, Mathews V, Trinkaus K, Khoury H, Adkins D, Vij R, Sempek D, Graubert T, Tomasson M, Goodnough LT, DiPersio JF
    Bone Marrow Transplant 2005 Sep;36(6):531-8
  • Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research
    Pavletic SZ, Khouri IF, Haagenson M, King RJ, Bierman PJ, Bishop MR, Carston M, Giralt S, Molina A, Copelan EA, Ringden O, Roy V, Ballen K, Adkins DR, McCarthy P, Weisdorf D, Montserrat E, Anasetti C
    J Clin Oncol 2005 Aug 20;23(24):5788-94
  • Pilot study of 13cis-retinoic acid+dexamethasone+alpha interferon as maintenance therapy following high-dose chemotherapy and autologous stem cell transplant for multiple myeloma
    Friedman J, Khoury H, Adkins D, Devine S, Nervi B, Edwards T, Dipersio J, Vij R
    Bone Marrow Transplant 2005 May;35(10):979-84
  • Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide
    Girgis M, Hallemeier C, Blum W, Brown R, Lin HS, Khoury H, Goodnough LT, Vij R, Devine S, Wehde M, Postma S, Oza A, Dipersio J, Adkins D
    Blood 2005 Apr 15;105(8):3035-41
  • Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants
    Hallemeier C, Girgis M, Blum W, Brown R, Khoury H, Goodnough LT, Vij R, Devine S, Wehde M, Postma S, Lin HS, Dipersio J, Adkins D
    Biol Blood Marrow Transplant 2004 May;10(5):310-9
  • Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma
    Hoerr AL, Gao F, Hidalgo J, Tiwari D, Blum KA, Mathews V, Adkins DR, Blum W, Devine S, Vij R, Goodnough LT, Dipersio JF, Khoury HJ
    J Clin Oncol 2004 Nov 15;22(22):4561-6
  • Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes
    Hidalgo JD, Krone R, Rich MW, Blum K, Adkins D, Fan MY, Brown R, Devine S, Graubert T, Blum W, Tomasson M, Goodnough LT, Vij R, DiPersio J, Khoury H
    Bone Marrow Transplant 2004 Oct;34(7):615-9
  • Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation
    Khoury H, Trinkaus K, Zhang MJ, Adkins D, Brown R, Vij R, Goodnough LT, Ma MK, McLeod HL, Shenoy S, Horowitz M, Dipersio JF
    Biol Blood Marrow Transplant 2003 Nov;9(11):714-21
  • Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility study
    Blum W, Khoury H, Lin HS, Vij R, Goodnough LT, Devine S, Dipersio J, Adkins D
    Biol Blood Marrow Transplant 2003 Jun;9(6):397-404
  • Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation
    Vij R, Khoury H, Brown R, Goodnough LT, Devine SM, Blum W, Adkins D, DiPersio JF
    Bone Marrow Transplant 2003 Oct;32(7):703-7
  • Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity
    Chohan R, Vij R, Adkins D, Blum W, Brown R, Tomasson M, Devine S, Graubert T, Goodnough LT, DiPersio JF, Khoury H
    Br J Haematol 2003 Oct;123(1):110-3
  • Granulocyte transfusions and cytomegalovirus infection
    Vij R, DiPersio J, Khoury H, Goodnough LT, Devine SM, Blum W, Adkins D
    Blood 2003;101:5092
  • Use of the anti-idiotype breast cancer vaccine 11D10 in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer
    Reece DE, Foon KA, Bhattarcharya-Chatterjee M, Adkins D, Broun ER, Connaghan DG, Dipersio JF, Holland HK, Howard DA, Hale GA, Klingemann HG, Munn RK, Raptis A, Phillips GL
    Clin Breast Cancer 2003 Feb;3 Suppl 4:S152-7
  • Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation
    Vij R, DiPersio JF, Venkatraman P, Trinkaus K, Goodnough LT, Brown RA, Khoury HJ, Devine SM, Oza A, Shenoy S, Blum W, Adkins D
    Blood 2003 Mar 1;101(5):2067-9
  • Recent advances in allogeneic hematopoietic stem-cell transplantation
    Devine SM, Adkins DR, Khoury H, Brown RA, Vij R, Blum W, DiPersio JF
    J Lab Clin Med 2003 Jan;141(1):7-32
  • Low-dose (550 cGy), single-exposure total body irradiation and cyclophosphamide: consistent, durable engraftment of related-donor peripheral blood stem cells with low treatment-related mortality and fatal organ toxicity
    Blum W, Brown R, Lin HS, Zehnbauer B, Khoury H, Goodnough LT, Westervelt P, Vij R, DiPersio J, Adkins D
    Biol Blood Marrow Transplant 2002;8(11):608-18
  • Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer
    Reece DE, Foon KA, Battacharya-Chatterjee M, Adkins D, Broun ER, Connaghan DG, Dipersio JF, Holland HK, Howard DS, Hale GA, Klingemann HG, Munn RK, Raptis A, Phillips GL
    Clin Breast Cancer 2001 Apr;2(1):52-8
  • Low incidence of transplantation-related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a low-dose (550 cGy) total body irradiation conditioning regimen
    Khoury H, Adkins D, Brown R, Pence H, Vij R, Goodnough LT, Westervelt P, Trinkaus K, Lin HS, DiPersio Y
    Biol Blood Marrow Transplant 2001;7(6):352-8
  • Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide
    Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D, Luger SM, Ma MK, Ley TJ, DiPersio JF
    Blood 2001 Jul 15;98(2):266-71
  • Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin
    Khoury H, Kashyap A, Adkins DR, Brown RA, Miller G, Vij R, Westervelt P, Trinkaus K, Goodnough LT, Hayashi RJ, Parker P, Forman SJ, DiPersio JF
    Bone Marrow Transplant 2001 May;27(10):1059-64
  • Resolution of psoriasis after allogeneic bone marrow transplantation for chronic myelogenous leukemia: late complications of therapy
    Adkins DR, Abidi MH, Brown RA, Khoury H, Goodnough LT, Vij R, Westervelt P, DiPersio JF
    Bone Marrow Transplant 2000 Dec;26(11):1239-41
  • Outcomes of high-dose chemotherapy and autologous stem cell transplant in isolated locally recurrent breast cancer: a multicenter evaluation
    Vij R, DiPersio J, Brown R, Trinkaus K, Abboud C, Meehan KR, Frenette G, Freytes C, Goodnough LT, Khoury H, Ponnuri J, Adkins D
    Bone Marrow Transplant 2000 Nov;26(9):947-53
  • Does early treatment with high-dose methylprednisolone alter the course of hepatic regimen-related toxicity?
    Khoury H, Adkins D, Brown R, Trinkaus K, Vij R, Miller G, Goodnough LT, DiPersio J
    Bone Marrow Transplant 2000 Apr;25(7):737-43
  • Adverse side-effects associated with G-CSF in patients with chronic myeloid leukemia undergoing allogeneic peripheral blood stem cell transplantation
    Khoury H, Adkins D, Brown R, Vij R, Westervelt P, Trinkaus K, Goodnough LT, DiPersio JF
    Bone Marrow Transplant 2000 Jun;25(11):1197-201
  • Allogeneic peripheral blood stem cell transplantation following CD34+ enrichment by density gradient separation
    Vij R, Brown R, Shenoy S, Haug JS, Kaesberg D, Adkins D, Goodnough LT, Khoury H, DiPersio J
    Bone Marrow Transplant 2000 Jun;25(12):1223-1228
  • Innovations in allogeneic stem-cell transplantation
    DiPersio JF, Khoury H, Haug J, Vij R, Adkins DR, Goodnough LT, Brown RA
    Semin Hematol 2000 Jan;37(1 Suppl 2):33-41
  • Effect of leukocyte compatibility on neutrophil increment after transfusion of granulocyte colony-stimulating factor-mobilized prophylactic granulocyte transfusions and on clinical outcomes after stem cell transplantation
    Adkins DR, Goodnough LT, Shenoy S, Brown R, Moellering J, Khoury H, Vij R, DiPersio J
    Blood 2000 Jun 1;95(11):3605-12
  • Immune reconstitution following allogeneic peripheral blood stem cell transplants
    Shenoy S, Mohanakumar T, Todd G, Westhoff W, Dunnigan K, Adkins DR, Brown RA, DiPersio JF
    Bone Marrow Transplant 1999 Feb;23(4):335-46
  • Tularemia--an unusual cause of a solitary pulmonary nodule in the post-transplant setting
    Naughton M, Brown R, Adkins D, DiPersio J
    Bone Marrow Transplant 1999 Jul;24(2):197-9
  • Successful treatment of cerebral toxoplasmosis in a marrow transplant recipient: contribution of a PCR test in diagnosis and early detection
    Khoury H, Adkins D, Brown R, Goodnough L, Gokden M, Roberts T, Storch G, DiPersio J
    Bone Marrow Transplant 1999 Feb;23(4):409-11
  • Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality
    Brown RA, Adkins D, Khoury H, Vij R, Goodnough LT, Shenoy S, DiPersio JF
    J Clin Oncol 1999 Mar;17(3):806-12
  • Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer
    Adkins D, Brown R, Trinkaus K, Maziarz R, Luedke S, Freytes C, Needles B, Wienski D, Fracasso P, Pluard T, Moriconi W, Ryan T, Hoelzer K, Safdar S, Rearden T, Rodriguez G, Khoury H, Vij R, DiPersio J
    J Clin Oncol 1999 Jul;17(7):2006-14
  • Donor-derived acute promyelocytic leukemia in a liver-transplant recipient
    Bodo I, Peters M, Radich JP, Hess J, Blinder M, Watson MS, Van Rheeden R, Natarajan S, Lowell JA, Brown R, DiPersio J, Adkins D
    N Engl J Med 1999 Sep 9;341(11):807-13
  • Essential thrombocythemia after allogeneic bone marrow transplantation for chronic myelogenous leukemia
    Khoury H, Adkins D, Zehnbauer B, Goodnough L, Brown R, Safdar S, DiPersio JF
    Bone Marrow Transplant 1998 Jul;22(1):107-9
  • Hydroxyethylstarch sedimentation by gravity ex vivo for red cell reduction of granulocyte apheresis components
    Adkins D, Johnston M, Walsh J, Spitzer G, Goodnough T
    J Clin Apheresis 1998;13(2):56-61
  • Granulocyte collection efficiency and yield are enhanced by the use of a higher interface offset during apheresis of donors given granulocyte- colony-stimulating factor
    Adkins D, Ali S, Despotis G, Dynis M, Goodnough LT
    Transfusion 1998 Jun;38(6):557-64
  • Treatment of resistant mantle cell lymphoma with allogeneic bone marrow transplantation
    Adkins D, Brown R, Goodnough LT, Khoury H, Popovic W, DiPersio J
    Bone Marrow Transplant 1998 Jan;21(1):97-9
  • Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies
    Brown RA, Adkins D, Goodnough LT, Haug JS, Todd G, Wehde M, Hendricks D, Ehlenbeck C, Laub L, DiPersio J
    J Clin Oncol 1997 Sep;15(9):3067-74
  • Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation
    Tsai T, Goodman S, Saez R, Schiller G, Adkins D, Callander N, Wolff S, Freytes CO
    Bone Marrow Transplant 1997 Nov;20(10):859-63
  • Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy
    Spitzer G, Adkins D, Mathews M, Velasquez W, Bowers C, Dunphy F, Kronmueller N, Niemeyer R, McIntyre W, Petruska P
    Bone Marrow Transplant 1997 Dec;20(11):921-30
  • A phase II study of repetitive cycles of dose-intense carboplatin plus paclitaxel chemotherapy and peripheral blood stem cells in metastatic breast cancer
    Ford C, Spitzer G, Reilly W, Adkins D
    Semin Oncol 1997 Oct;24(5 Suppl 17):S17-81-S17-86
  • Resolution of invasive central nervous system aspergillosis in a transplant recipient [see comments]
    Khoury H, Adkins D, Miller G, Goodnough L, Brown R, DiPersio J
    Bone Marrow Transplant 1997 Jul;20(2):179-80
  • Indium-labeled white blood cells apheresed from donors receiving G-CSF localize to sites of inflammation when infused into allogeneic bone marrow transplant recipients
    Adkins D, Goodgold H, Hendershott L, Johnston M, Cravens D, Spitzer G
    Bone Marrow Transplant 1997 Apr;19(8):809-12
  • Transfusions of granulocyte-colony-stimulating factor-mobilized granulocyte components to allogeneic transplant recipients: analysis of kinetics and factors determining posttransfusion neutrophil and platelet counts
    Adkins D, Spitzer G, Johnston M, Velasquez W, Dunphy F, Petruska P
    Transfusion 1997 Jul;37(7):737-48
  • Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis
    Peters BG, Adkins DR, Harrison BR, Velasquez WS, Dunphy FR, Petruska PJ, Bowers CE, Niemeyer R, McIntyre W, Vrahnos D, Auberry SE, Spitzer G
    Bone Marrow Transplant 1996 Jul;18(1):93-102
  • Malignancy-associated pulmonary veno-occlusive disease: report of a case following autologous bone marrow transplantation and review
    Salzman D, Adkins DR, Craig F, Freytes C, LeMaistre CF
    Bone Marrow Transplant 1996 Oct;18(4):755-60
  • Randomized in vitro study of G-CSF (priming) vs (no priming) prior to high-dose therapy (HDT) with cyclophosphamide-etoposide-cisplatin (CVP)
    Rodriguez J, Dunphy F, Spitzer G, Velasquez W, Petruska P, Adkins D, Bowers C, Broun G, Broun R
    In: Autologous Marrow and Blood Transplantation. Proceedings of the Seventh International Symposium held in Arlington, TX August 17-20, 1994, Eds. Karel A. Dicke and Armand Keating, pp 557-562, 1995
  • Repetitive high-dose therapy: Tolerance and outcome in stage IV breast cancer
    Spitzer G, Champlin R, Scong D, Dunphy F, Velasquez W, Petruska P, Bowers C, Broun G, McIntyre W, Niemeyer R, Adkins DR
    Proceedings of the Seventh International Symposium held in Arlington, TX August 17-20, 1994, Eds. Karel A. Dicke and Armand Keating, pp 195-205, 1995
  • Irreversible, severe congestive cardiomyopathy occurring in association with interferon alpha therapy
    Zimmerman S, Adkins D, Graham M, Petruska P, Bowers C, Vrahnos D, Spitzer G
    Cancer Biother 1994 Winter;9(4):291-9
  • Persistent problems of neutropenia and thrombocytopenia with peripheral blood stem cell transplantation
    Spitzer G, Adkins DR
    J Hematother 1994 Fall;3(3):193-8
  • Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit [see comments]
    Spitzer G, Adkins DR, Spencer V, Dunphy FR, Petruska PJ, Velasquez WS, Bowers CE, Kronmueller N, Niemeyer R, McIntyre W
    J Clin Oncol 1994 Apr;12(4):661-70
  • Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma
    Adkins DR, Salzman D, Boldt D, Kuhn J, Irvin R, Roodman GD, Lyons R, Smith L, Freytes CO, LeMaistre CF
    J Clin Oncol 1994 Sep;12(9):1890-901
  • High-dose therapy with stem cell support in solid tumors
    Spitzer G, Dunphy FR, Bowers CE, Adkins DR
    Med Oncol 1994;11(2):53-62
  • Dose escalation of mitoxantrone given with thiotepa and autologous bone marrow transplantation for metastatic breast cancer
    Bowers C, Adkins D, Dunphy F, Harrison B, LeMaistre CF, Spitzer G
    Bone Marrow Transplant 1993 Nov;12(5):525-30
  • Design of preparative regimens for stem cell transplantation in breast cancer
    Spitzer G, Adkins D, Dunphy F, Petruska P, Spencer V, Velasquez W
    Breast Cancer Res Treat 1993;26 Suppl:S3-9
  • A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors
    Adkins DR, Irvin R, Kuhn J, Boldt DH, Roodman GD, Salzman D, Freytes C, Von Hoff DD, LeMaistre CF
    Invest New Drugs 1993 May-Aug;11(2-3):169-79
  • Tandem transplants in solid tumors: marrow versus peripheral stem cell transplant: peripheral blood cells as now practiced are not the whole answer
    Spitzer G, Dunphy FR 2d, Petruska PJ, Velasquez WS, Adkins DR
    J Hematother 1993 Fall;2(3):363-5
  • Durable complete remission in a patient with refractory mediastinal non- seminomatous germ cell tumor after tandem high-dose chemotherapy and autologous bone marrow transplantation
    Adkins D, Encarnacion C, Salzman D, Boldt D, Freytes C, Von Hoff DD, LeMaistre CF
    Bone Marrow Transplant 1993 Nov;12(5):541-6